Domestic antibiotic production industry will be a tragic "killing"

at present, the traditional bulk API production has formed a reverse transformation trend, the entire industry is at a crossroadsDubbed "the most severe anti-resistance order in history", the "Clinical Application Management Measures for Antibacterial Drugs" was officially implemented on August 1, 2012, and the restriction of antimicrobial drugs is becoming more normalThis is highly competitive, product homogenization of serious domestic antibiotic production industry, will undoubtedly "kill" even more tragicwqt
Domestic antibiotic production industry will be a tragic "killing"wqtthe current traditional bulk raw materials market encountered multiple dilemmas: First, the deteriorating foreign trade environmentEurope and the United States entered the post-subprime crisis era, demand decline, slow development, increased trade barriers, the European Union, the United States and other major export markets have raised the import thresholdSecond, the domestic accumulation of many years of overcapacity outbreak, domestic and export market demand is weak, especially the domestic "limited resistance" policy on the demand for antibioticraw materials, vitamin C and other core varieties of prices below the cost priceThird, environmental protection requirements are getting higher and higherThe determination of the state to clean up the environment is growing, the price of raw materials produced by enterprises continues to rise, and production costs have increased significantlywqt
It is understood that in July 2011 the European Union issued Directive 2011/62/EU (Preventing counterfeit drugs from entering the legal supply chain) in order to prevent the flow of counterfeit drugs into the regular distribution channelsThe Directive stipulates that from July 2013, all drugs exported to the EU will be subject to a written statement from the regulator of the exporting country and shall ensure compliance with the following requirements: first, thewqt is that the GMP regulations of the exporting country are equivalent to EU standards; In fact, the directive raised concerns in the industry as soon as it was introduced in 2011 The EU is China's largest export market for API products, accounting for about 25% of China's total global API exports and 83% of The total exportof ossie wqt at present, the traditional bulk API production has formed a reverse transformation trend, the entire industry is at a crossroads Dubbed "the most severe anti-resistance order in history", the "Clinical Application Management Measures for Antibacterial Drugs" was officially implemented on August 1, 2012, and the restriction of antimicrobial drugs is becoming more normal This is highly competitive, product homogenization of serious domestic antibiotic production industry, will undoubtedly "kill" even more tragic wqt
　　Domestic antibiotic production industry will be a tragic "killing" wqt the current traditional bulk raw materials market encountered multiple dilemmas: First, the deteriorating foreign trade environment Europe and the United States entered the post-subprime crisis era, demand decline, slow development, increased trade barriers, the European Union, the United States and other major export markets have raised the import threshold Second, the domestic accumulation of many years of overcapacity outbreak, domestic and export market demand is weak, especially the domestic "limited resistance" policy on the demand for antibioticraw materials, vitamin C and other core varieties of prices below the cost price Third, environmental protection requirements are getting higher and higher The determination of the state to clean up the environment is growing, the price of raw materials produced by enterprises continues to rise, and production costs have increased significantly wqt
　　It is understood that in July 2011 the European Union issued Directive 2011/62/EU (Preventing counterfeit drugs from entering the legal supply chain) in order to prevent the flow of counterfeit drugs into the regular distribution channels The Directive stipulates that from July 2013, all drugs exported to the EU will be subject to a written statement from the regulator of the exporting country and shall ensure compliance with the following requirements: first, the wqt is that the GMP regulations of the exporting country are equivalent to EU standards; In fact, the directive raised concerns in the industry as soon as it was introduced in 2011 The EU is China's largest export market for API products, accounting for about 25% of China's total global API exports and 83% of The total exportof ossie wqt